Clinical and demographic features of CLAAS cohort.
| Features | N (%) |
|---|---|
| Clinical features | |
| Hematologic (any) | 46 (92) |
| Anemia | 42 (84) |
| Leukopenia | 33 (66) |
| Neutropenia | 23 (46) |
| Renal | 39 (78) |
| Dermatologic (any) | 29 (58) |
| Purpura/ulcers | 21 (42) |
| MSK | 20 (40) |
| ENT | 5 (10) |
| Pulmonary | 2 (4) |
| Laboratory features | |
| Antiphospholipid antibody (any) | 19/28 (68) |
| Anticardiolipin IgM | 18/28 (64) |
| Anticardiolipin IgG | 5/28 (18) |
| Anti-β2 glycoprotein IgM | 9/24 (38) |
| Anti-β2 glycoprotein IgG | 3/28 (11) |
| Lupus inhibitor | 15/19 (79) |
| Evidence of HCV exposure | 32/48 (67) |
| HCV viremia | 23/49 (47) |
| Evidence of HIV infection | 3/47 (6) |
| Low C3 or C4 | 15/33 (45) |
| Cryoglobulinemia | 8/28 (29) |
| RF | 8/33 (24) |
| ANA | 11/48 (23) |
| Levamisole detected in urine | 14/36 (39) |
CLAAS: cocaine/levamisole-associated autoimmunity syndrome; MSK: musculoskeletal; HCV: hepatitis C virus; HIV: human immunodeficiency virus; RF: rheumatoid factor; ANA: antinuclear antibody; IgM: immunoglobulin M.